An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

Brief description of study

The purpose of the study is to determine the safety and efficacy of INCMGA00012 monotherapy or in combination with other immunotherapy or targeted agents (combinations of INCMGA00012 with epacadostat and pemigatinib) for participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. INCMGA00012 is a humanized, hinge-stabilized, IgG4? monoclonal antibody that recognizes human PD-1. The study drug INCMGA00012 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s20-01346
ClinicalTrials.gov Identifier: NCT04463771
Principal Investigator: Bhavana Pothuri.
Other Investigators: Christina Grace Wilson, Marina Stasenko, Michelle Diane Swanson Lightfoot, Carol M Lee, Erin Annette Reese, Jonathan B Kahn, Whitfield B. Growdon, Caitlin Elizabeth Ryan, Kathleen M Lutz, Leslie R Boyd.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.